Seoulin Bioscience Co.,Ltd.

KOSDAQ:A038070 Stock Report

Market Cap: ₩61.5b

Seoulin BioscienceLtd Past Earnings Performance

Past criteria checks 0/6

Seoulin BioscienceLtd's earnings have been declining at an average annual rate of -19.5%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 10.2% per year.

Key information

-19.5%

Earnings growth rate

-19.3%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate10.2%
Return on equity-3.6%
Net Margin-0.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Low P/S No Reason For Excitement

Dec 04
Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Low P/S No Reason For Excitement

Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Is An Attractive Dividend Stock - Here's Why

May 03
Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Is An Attractive Dividend Stock - Here's Why

Should Weakness in Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Mar 13
Should Weakness in Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Introducing Seoulin BioscienceLtd (KOSDAQ:038070), A Stock That Climbed 54% In The Last Year

Feb 15
Introducing Seoulin BioscienceLtd (KOSDAQ:038070), A Stock That Climbed 54% In The Last Year

Is Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) A Great Dividend Stock?

Jan 20
Is Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) A Great Dividend Stock?

Three Days Left Until Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Trades Ex-Dividend

Dec 25
Three Days Left Until Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Trades Ex-Dividend

Is Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Dec 06
Is Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Revenue & Expenses Breakdown

How Seoulin BioscienceLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A038070 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2482,093-66214,507961
30 Jun 2484,514-59114,713818
31 Mar 2485,821-1,35714,350738
31 Dec 2389,569-11814,954785
30 Sep 2383,8783,30714,276890
30 Jun 2386,5383,94514,311906
31 Mar 23100,6379,86913,351904
31 Dec 22104,70810,12912,928870
30 Sep 22103,5708,76512,983753
30 Jun 22103,58620,65012,460742
31 Mar 2289,47516,31512,071755
31 Dec 2180,53915,70011,172787
30 Sep 2180,21917,67010,199809
30 Jun 2175,1055,8909,850915
31 Mar 2167,6895,3539,603970
31 Dec 2065,0854,8939,522998
30 Sep 2062,5204,2519,7881,077
30 Jun 2058,3494,0689,784955
31 Mar 2057,0429,4379,989985
31 Dec 1954,4108,8849,861955
30 Sep 1950,7568,59010,1721,135
30 Jun 1951,7008,34610,2701,184
31 Mar 1951,2312,64010,1131,183
31 Dec 1849,8772,62510,0281,190
30 Sep 1847,4442,3149,9731,126
30 Jun 1843,5121,7149,6481,085
31 Mar 1842,3171,5409,659983
31 Dec 1742,6192,0619,495998
30 Sep 1744,4373,0088,774857
30 Jun 1744,9373,0079,272679
31 Mar 1746,6984,7109,266668
31 Dec 1644,8894,0738,768795
30 Sep 1644,3143,5999,033661
30 Jun 1643,4813,2308,915661
31 Mar 1642,0441,7728,368644
31 Dec 1541,6281,8258,242566
30 Sep 1541,5381,9527,871591
30 Jun 1539,6822,2577,769591
31 Mar 1537,7542,0938,078630
31 Dec 1437,6622,6688,147744
30 Sep 1434,8612,2438,290945
30 Jun 1436,0593,2247,246945
31 Mar 1439,5013,8615,354913
31 Dec 1342,1964,1605,6341,046

Quality Earnings: A038070 is currently unprofitable.

Growing Profit Margin: A038070 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A038070 is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare A038070's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A038070 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A038070 has a negative Return on Equity (-3.65%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 04:36
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Seoulin Bioscience Co.,Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sung Hwan ChoiKyobo Securities Co., Ltd
Ju-Hong ChoeLS Securities Co., Ltd.
Seung KimSK Securities Co., Ltd.